InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (7 ops.)
Insider track record
ExecutiveDisclosed buys
1
Disclosed sells
7
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Haviland Kate, Chief Operating Officer. Director active across 1 company, notably Blueprint Medicines Corp. Aggregated, 16 filings have been published. Split: 1 buy · 7 sells. Total volume traded: €3m. History available since 28 June 2021. The latest transaction was filed on 1 April 2025 (Cession). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Haviland Kate
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations16 total
129,210 sharesCommon StockSEC:0001104659-25-069386:0
600 shares@ US$85.471.5% of flowCommon StockSEC:0001415889-25-009959:0
16,151 shares@ US$88.8041.8% of flowCommon StockSEC:0001415889-25-007384:0
35,200 shares0Common StockSEC:0001415889-25-006606:0
1,446 shares@ US$110.244.7% of flowCommon StockSEC:0001415889-25-001993:0
400 shares@ US$95.401.1% of flowCommon StockSEC:0001415889-24-028171:0
12,464 shares@ US$90.6932.1% of flowCommon StockSEC:0001415889-24-007560:0
40,000 shares0Common StockSEC:0001415889-24-007011:0
6,428 shares@ US$45.728.6% of flowCommon StockSEC:0001415889-23-004555:0
40,000 shares0Common StockSEC:0001415889-23-004261:0
1,100 shares@ US$43.981.5% of flowCommon StockSEC:0001415889-22-011111:0
Canonical exit: 1 Feb 2023 (T+90)
1,719 shares@ US$60.273.0% of flowCommon StockSEC:0001415889-22-002733:0
40,000 shares0Common StockSEC:0001415889-22-002440:0
1,000 shares@ US$36.051.0% of flowCommon StockSEC:0001179110-21-010988:0
1,000 shares@ US$36.051.0% of flowCommon StockSEC:0001179110-21-008782:0
1,000 shares@ US$36.051.0% of flowCommon StockSEC:0001179110-21-007172:0
16 of 16 declarations
About Haviland Kate
Haviland Kate is Directeur des Opérations and appears in 16 filings in total. Across the 16 sampled filings from 2021-06-30 to 2025-07-21, the observed transactions are mainly sales, with 49,293 EUR of buys and 2,993,063 EUR of sells, including activity in Blueprint Medicines Corp, where she is Chief Executive Officer.
